If you have been reading about angiogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-15. Numbers and descriptions here follow the published literature rather than marketing material.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
=== Acute toxicity === Although a low dosis of arenobufagin can be used as a medicine to treat heart rate problems, a high dose can lead to acute heart problems and even death. Arenobufagin is also toxic for hepatocellular carcinoma cells, which is a positive result for the body.
=== Advantages === In the early 1970s, the Alza Corporation, through their founder Alejandro Zaffaroni, filed the first US patents describing transdermal delivery systems for scopolamine, nitroglycerin and nicotine. People found that applying medicines on the body surfaces is beneficial in many aspects. Skin medicines can give faster onset and local effect on our body as the surface cream can bypass first pass metabolism such as hepatic and intestinal metabolism. Apart from the absorption, dermal drugs effectively prevent oral delivery limitations such as nausea and vomiting and poor appliances due to unpalatable tastes of the drugs . Topical application is an easy way for patients to tackle skin infections in a painless and non-invasive way. From a patient perspective, applying drugs on skin also provides stable dosage in blood so as to give the optimal bioavailability and therapeutic effects. In case of overdose or unwanted side effects, patients can take off or wash out the medicines quickly to eliminate toxicity by simply removing the patch to stop the delivery of drugs.
Since May 2017, Holick has been barred from evaluating or treating children by Boston Medical Center, which subsequently reported him to the Massachusetts Board of Registration in Medicine for "health care facility discipline", but is still allowed to evaluate children who are participating in his research project. Boston University has defended Holick's right to testify in courts, as part of his academic freedom. Holick has speculated that the dinosaurs may have died of rickets and osteomalacia caused by a lack of vitamin D in reduced sunlight. A paper on vitamin D to treat COVID-19 has been retracted.
== Structure == DNA and RNA have a deoxyribose and ribose sugar backbone, respectively, whereas PNA's backbone is composed of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. The various purine and pyrimidine bases are linked to the backbone by a methylene bridge (−CH2−) and a carbonyl group (C=O). PNAs are depicted like peptides, with the N-terminus at the first (left) position and the C-terminus at the last (right) position.
Sources: en.wikipedia.org
=== Examples === 1 IU of rhEGF is defined as the potency of 0.001 μg of a rhEGF in the "91/530" standard vial. One manufacturer reports that its rhEGF is 1.4 times as potent as the 91/530 standard. 12.5 IU of oxytocin is defined as the potency of 21 μg of pure peptide in the "76/575" standard vial. Before the purification of penicillin was perfected, the amounts were also described in "International Units" (and some non-international arbitrary "units" before them) to account for batch-to-batch variation. See Penicillin § Penicillin units.
== History == Fenethylline was first synthesized by the German pharmaceutical firm Degussa AG in 1961 and used for around 25 years as a milder alternative to amphetamine and related compounds. Although there are no FDA-approved indications for fenethylline, it was used in the treatment of "hyperkinetic children", in what would now be called attention deficit hyperactivity disorder, and, less commonly, for narcolepsy and depression. One of the main advantages of fenethylline was that it does not increase blood pressure to the same extent as an equivalent dose of amphetamine and so could be used in patients with cardiovascular conditions. Fenethylline was considered to have fewer side effects and less potential for abuse than amphetamine. However, because its chemical composition is similar to amphetamine's, fenethylline was listed in 1981 as a Schedule I controlled substance in the United States, and it became illegal in most countries in 1986 after being listed by the World Health Organization for international scheduling under the Convention on Psychotropic Substances.
== S == Salmonella Salmonella enteritidis Salmonella typhi Salmonella typhimurium Serratia marcescens Shewanella algae Shigella Shigella dysenteriae Shigella sonnei Spirillum volutans Staphylococcus Staphylococcus aureus Methicillin-resistant Staphylococcus aureus Staphylococcus epidermidis Staphylococcus lugdunensis Staphylococcus saprophyticus Stenotrophomonas maltophilia Streptococcus Streptococcus agalactiae Streptococcus anginosus Streptococcus avium Streptococcus bovis Streptococcus constellatus Streptococcus cricetus Streptococcus ferus Streptococcus intermedius Streptococcus lactis Streptococcus mitior Streptococcus mitis Streptococcus mutans Streptococcus oralis Streptococcus pneumoniae Streptococcus pyogenes Streptococcus rattus Streptococcus salivarius Streptococcus sobrinus Streptomyces avermitilis
== Research == Some related pyrrylphenylethanones had analgesic activity comparable to morphine. Some pyrrole analogues were reported to have analgesic effects comparable to lefetamine and being devoid of neurotoxic properties.
=== Speed of change === VVM types are indicated by a number after "VVM". The number refers to the number of days required for the VVM to reach the discard-point (circle) color at 37 °C (99 °F). For example, VVM7 takes 7 days to turn at 37 degrees. Four main types are in use to match to the degradation rates of different vaccines: VVM30 (HepB, BCG, tetanus), VVM14 (measles, MMR), VVM7 (DPT), and VVM2 (OPV). VVM11 and VVM250 are also available. VVMs work because almost every chemical reaction corresponds to the Arrhenius equation, exponentially speeding up as the temperature increases. When time-to-change-color for a VVM or the time-to-degrade for a vaccine are plotted against the temperature on an log-linear plot, the points tend to fall in a straight line as predicted by Arrhenius (Arrhenius graph). The straight line can therefore be used to both interpolate and extrapolate the time-to-change/degrade at any given temperature. To choose the right VVM for a vaccine, one matches the known vaccine endurance data points against an Arrhenius graph of VVMs.
Sources: en.wikipedia.org
Canned (tinned) instant soups contain liquid soup that is prepared by heating their contents. Some canned soups are condensed, and require additional water to bring them to their intended strength, while others are canned in a ready-to-eat, single-strength form. Dr. John T. Dorrance, an employee with the Campbell Soup Company, invented condensed soup in 1897. Consumers sometimes use condensed soups (without diluting them), as a sauce base. Some instant liquid soups are manufactured in microwaveable containers. Additionally, some instant soups, such as Knorr's Erbswurst, are prepared in a concentrated paste form. Knorr ceased production of Erbswurst on December 31, 2018. Instant noodle soups such as Cup Noodles contain dried instant ramen noodles, dehydrated vegetable and meat products, and seasonings, and are prepared by adding hot water. Packaged instant ramen noodle soup is typically formed as a cake, and often includes a seasoning packet that is added to the noodles and water during preparation. Some also include separate packets of oil and garnishes used to season the product. Momofuku Ando, the founder of Nissin Foods, developed packaged ramen noodle soup in 1958.
==== Malaysia ==== Another example is the Malaysian states of Sabah and Sarawak, which have maintained their own border controls since joining Malaysia in 1963. The internal border control is asymmetrical: while Sabah and Sarawak impose immigration controls on Malaysian citizens from other states, there is no corresponding border control in Peninsular Malaysia, and Malaysians from Sabah and Sarawak have an unrestricted right to live and work in the Peninsular. For social and business visits of less than three months, Malaysian citizens may travel between the Peninsular, Sabah, and Sarawak using the Malaysian identity card (MyKad) or Malaysian passport, while for longer stays in Sabah and Sarawak, they are required to have an Internal Travel Document or a passport with the appropriate residential permit.
Furthermore, a nanoparticle could possess the capability to be activated by a trigger that is specific to the target site, such as utilizing materials that are pH responsive. Most of the body has a consistent, neutral pH. However, some areas of the body are naturally more acidic than others, and, thus, nanoparticles can take advantage of this ability by releasing the drug when it encounters a specific pH. Another specific triggering mechanism is based on the redox potential. One of the side effects of tumors is hypoxia, which alters the redox potential in the vicinity of the tumor. By modifying the redox potential that triggers the payload release the vesicles can be selective to different types of tumors. By utilizing both passive and active targeting, a drug-loaded nanoparticle has a heightened advantage over a conventional drug. It is able to circulate throughout the body for an extended period of time until it is successfully attracted to its target through the use of cell-specific ligands, magnetic positioning, or pH responsive materials. Because of these advantages, side effects from conventional drugs will be largely reduced as a result of the drug-loaded nanoparticles affecting only diseased tissue. However, an emerging field known as nanotoxicology has concerns that the nanoparticles themselves could pose a threat to both the environment and human health with side effects of their own. Active targeting can also be achieved through peptide based drug targeting system.
== Applications == The primary application for ion-to-photon detectors is acting as the detector in MALDI mass spectrometry. They could, in theory, be used for other types of mass spectrometry as well.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.